ArticleScientific reports2026
Skin cancer detection using late fusion of pretrained models.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Skin cancer is one of the most common and fatal malignancies worldwide, and reliable, early diagnosis systems are required to provide effective clinical intervention. Nevertheless, even with recent progress in deep learning, current models tend to overfit and lack generalizability and robustness across various lesion types. This paper overcomes these challenges by presenting a late-fusion ensemble of pre-trained convolutional neural networks (CNNs) integrated with Diverse Convolution Networks (DCNs) to build a complementary and discriminative skin cancer detection framework from dermoscopic images. The study utilized a curated dataset of 10,600 dermoscopic images from the ISIC Archive, comprising 9600 images for training and 1000 images for testing, encompassing both malignant and benign lesion classes. The proposed late-fusion model combines the predictions of several pre-trained architectures, leveraging their strengths while mitigating bias. Experimental results show excellent performance with an accuracy of 99.7%, an F1-score of 99.75%, a precision of 99.12%, and a recall of 99.34% on the test set, and an accuracy of 99.1% and an F1-score exceeding state-of-the-art models of 99.8% on the melanoma dataset. The conclusions validate the robustness and diagnostic accuracy of the framework in complex clinical situations. Future work will focus on model explainability, integration with clinical decision support systems, and validation using larger, multi-source datasets to enhance real-world applicability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.